Form 4: Rhythm Pharma Exec Granted 21,650 RSUs, 32,500 Options

Rhythm Pharmaceuticals' EVP, Head of North America, Jennifer Kayden Lee, received grants of restricted stock units and stock options.

Summary

• Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, Inc. (RYTM), was granted 21,650 Restricted Stock Units (RSUs) on February 11, 2026.
• Each RSU represents a contingent right to receive one share of Issuer common stock.
• The RSUs vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029, and February 1, 2030.
• Lee also received a grant of 32,500 stock options with an exercise price of $98.47 on February 11, 2026.
• These stock options expire on February 10, 2036.
• The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, indicating executive retention and alignment with shareholder interests through long-term equity incentives, which is a standard and healthy practice.

Positives

• The grants of restricted stock units and stock options align the executive's interests with long-term shareholder value creation.
• The multi-year vesting schedules for both RSUs and stock options incentivize continued service and performance from a key executive.

Future Outlook

This Form 4 filing primarily reports past transactions (equity grants) and their future vesting schedules, rather than providing a general future outlook for the company. It indicates a long-term commitment from a key executive through incentive-based compensation.

Industry Context

StockSavvy.ai notes that equity grants to key executives like an EVP, Head of North America, are standard practice in the biotechnology and pharmaceutical industry. These grants are crucial for attracting and retaining top talent, especially in companies like Rhythm Pharmaceuticals that are focused on developing and commercializing novel therapies for rare diseases. Such compensation structures are designed to align executive incentives with the long-term success and shareholder value creation, which is particularly important in an industry with long development cycles and high R&D costs.

Comparison to Industry Standards

• The grant of RSUs and stock options with multi-year vesting schedules is consistent with executive compensation practices observed at comparable biopharmaceutical companies such as Sarepta Therapeutics (SRPT) or Vertex Pharmaceuticals (VRTX), where long-term incentive plans form a significant portion of executive pay.
• The specific number of units and options granted would typically be benchmarked against peer group companies of similar market capitalization and stage of development, reflecting the executive's role and performance expectations.

Stakeholder Impact

• Shareholders: The grants align executive incentives with long-term shareholder value, potentially fostering sustained growth.
• Employees: Standard executive compensation practices can positively influence overall employee morale and retention strategies within the company.

Next Steps

• The restricted stock units will begin vesting on February 1, 2027, with subsequent vesting dates on February 1, 2028, 2029, and 2030.
• The stock options will vest in 16 substantially equal installments upon completion of each three full months of successive service following the grant date of February 11, 2026.

Key Dates

Recommendation

This Form 4 filing reports routine equity grants to a key executive, which is a standard practice for executive compensation and retention. While it indicates continued alignment of management interests with shareholders, it does not provide new fundamental information about the company's operational performance or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals.

Keywords

Rhythm Pharmaceuticals, RYTM, Jennifer Kayden Lee, Restricted Stock Units, Stock Options, Insider Transaction, Executive Compensation, Equity Grant